… To measure “Advancement of technology”, Kolasa et al. (34) made a distinction between
Advanced therapy medicinal products (ATMPs), complex drugs, small molecules (with at least …

… Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November
2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and …

… The arrival of advanced therapy medicinal products (ATMPs) and, in particular, those … in
these assessments are the Health Technology Assessment (HTA) bodies. HTA bodies assess …

… considerations for the deliberative appraisal of pharmaceutical products with overlap on …
for example, the Medical Device and Health Technology Evaluation Committee at HAS includes …

… Among innovative therapies, there is a … Advanced Therapy Medicinal Products (ATMPs) in
Europe, that include somatic cell therapies, gene therapies and tissue-engineered products [2]…

… such as health technology assessment (HTA) bodies have to make critical reimbursement
decisions, balancing a product's … (EC) No 1394/2007 on advanced therapy medicinal products. …

… of an autologous gene therapy medicine and illuminated where product, process and … drug
product can be administered in an ex vivo or in vivo setting. Ex vivo autologous gene therapy …

More than two million medical students, doctors and other health professionals around the
globe have owned a copy of Davidson’s Principles and Practice of Medicine since it was first …

… ’ of advanced therapies: limited … a healthcare provider (eg a hospital) or at a ‘higher-level’
governance institution, such as a Health Technology Assessment (HTA) (if it is a therapeutic or …

… advanced therapy medicinal products … are usually included as an Advanced Therapy
Medicinal Product (ATMP) in … followup-risk management of advanced therapy medicinal products …